Concentration-guided ribavirin dosing with darbepoetin support and peg-IFN alfa-2a for treatment of hepatitis C recurrence after liver transplantation

Journal of Viral Hepatitis

Volumn 19, Issue 9, 2012, Pages 635-639

  Ackefors, M ^a   Gjertsen, H ^a   Wernerson, A ^a   Weiland, O ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

hepatitis C virus; peg IFN; ribavirin

Indexed keywords

CREATININE; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ANEMIA; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG TOLERABILITY; DRUG TOLERANCE; FEMALE; GENOTYPE; HEALTH CARE QUALITY; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; KIDNEY FUNCTION; KIDNEY MASS; LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER TRANSPLANTATION; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECURRENT INFECTION; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; DRUG MONITORING; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN; FEMALE; HEPATITIS C; HUMANS; INTERFERON-ALPHA; LIVER TRANSPLANTATION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RECURRENCE; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84864688226     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2012.01587.x     Document Type: Article

References (20)

1. Berenguer M,. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49 (2): 274-287.
2. Gjertsen H, Weiland O, Oksanen A, Soderdahl G, Broome U, Ericzon BG,. Liver transplantation for HCV cirrhosis at Karolinska University Hospital Huddinge, Stockholm. Transplant Proc 2006; 38 (8): 2675-2676. (Pubitemid 44693657)
3. Melum E, Friman S, Bjoro K, et al. Hepatitis C impairs survival following liver transplantation irrespective of concomitant hepatocellular carcinoma. J Hepatol 2007; 47 (6): 777-783. (Pubitemid 350051112)
4. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR,. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122 (4): 889-896. (Pubitemid 34267271)
5. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 13: 815-820. (Pubitemid 26099603)
6. Dixon LR, Crawford JM,. Early histologic changes in fibrosing cholestatic hepatitis C. Liver Transpl 2007; 13 (2): 219-226. (Pubitemid 46351647)
7. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347 (13): 975-982.
8. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140 (5): 346-355.
9. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358 (9286): 958-965. (Pubitemid 32913521)
10. Bzowej N, Nelson DR, Terrault NA, et al. PHOENIX: a randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl 2011; 17 (5): 528-538.
11. Berenguer M,. Treatment of chronic hepatitis C in hemodialysis patients. Hepatology 2008; 48 (5): 1690-1699.
12. Bruchfeld A, Lindahl K, Stahle L, Soderberg M, Schvarcz R,. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 2003; 18 (8): 1573-1580. (Pubitemid 36939631)
13. Lindahl K, Schvarcz R, Bruchfeld A, Stahle L,. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J Viral Hepat 2004; 11 (1): 84-87. (Pubitemid 38221622)
14. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R,. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005; 41 (2): 275-279. (Pubitemid 40165370)
15. Batts KP, Ludwig J,. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19 (12): 1409-1417.
16. Lagging M, Wejstal R, Uhnoo I, et al. Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations. Scand J Infect Dis 2009; 41 (6-7): 389-402.
17. Rowland M, Tozer T,. Clinical Pharmacokinetics, Concepts and Applications, 3rd edn. Williams & Wilkins, 1995.
18. Selzner N, Guindi M, Renner EL, Berenguer M,. Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. J Hepatol 2011; 55 (1): 207-217.
19. Hornfeldt E, Gjertsen H, Weiland O,. High adherence with a low initial ribavirin dose in combination with pegylated-IFN alpha-2a for treatment of recurrent hepatitis C after liver transplantation. Scand J Infect Dis 2008; 40 (3): 259-265. (Pubitemid 351260436)
20. Roche B, Samuel D,. Is early antiviral therapy for recurrent hepatitis C after liver transplantation superior to later treatment? The answer is no. Liver Transpl 2011; 17 (5): 488-491.